BRPI0817937A2 - Entrega mediada por aav autocomplementar de moléculas de rna de interferência para tratar ou prevenir distúrbios oculares - Google Patents

Entrega mediada por aav autocomplementar de moléculas de rna de interferência para tratar ou prevenir distúrbios oculares

Info

Publication number: BRPI0817937A2
Authority: BR; Brazil
Prior art keywords: complementing; treat; self; rna molecules; interfering rna
Prior art date: 2007-10-01

Application number

Other languages

English (en)

Inventor

Allan R Shepard

Original Assignee

Alcon Res Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-01

Filing date

2008-10-01

Publication date

2015-04-07

2008-10-01 Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd

2015-04-07 Publication of BRPI0817937A2 publication Critical patent/BRPI0817937A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Ophthalmology & Optometry (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

BRPI0817937 2007-10-01 2008-10-01 Entrega mediada por aav autocomplementar de moléculas de rna de interferência para tratar ou prevenir distúrbios oculares BRPI0817937A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97655207P	2007-10-01	2007-10-01
PCT/US2008/078380 WO2009046059A1 (en)	2007-10-01	2008-10-01	Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders

Publications (1)

Publication Number	Publication Date
BRPI0817937A2 true BRPI0817937A2 (pt)	2015-04-07

Family

ID=40042637

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817937 BRPI0817937A2 (pt)	2007-10-01	2008-10-01	Entrega mediada por aav autocomplementar de moléculas de rna de interferência para tratar ou prevenir distúrbios oculares

Country Status (12)

Country	Link
US (1)	US20090087413A1 (pt)
EP (1)	EP2192926A1 (pt)
JP (1)	JP2010540564A (pt)
KR (1)	KR20100061792A (pt)
CN (1)	CN101815536A (pt)
AU (1)	AU2008308784B2 (pt)
BR (1)	BRPI0817937A2 (pt)
CA (1)	CA2694091A1 (pt)
MX (1)	MX2010001608A (pt)
RU (1)	RU2010117178A (pt)
WO (1)	WO2009046059A1 (pt)
ZA (1)	ZA201000423B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2019143A1 (en)	2007-07-23	2009-01-28	Genethon	CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en)	2007-10-05	2009-05-13	Genethon	Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2287323A1 (en) *	2009-07-31	2011-02-23	Association Institut de Myologie	Widespread gene delivery to the retina using systemic administration of AAV vectors
EA035893B1 (ru) *	2010-04-23	2020-08-27	Юниверсити Оф Флорида Рисерч Фаундейшн, Инк.	РЕКОМБИНАНТНЫЙ АДЕНОАССОЦИИРОВАННЫЙ ВИРУСНЫЙ ВЕКТОР (rAAV), КОДИРУЮЩИЙ БИОЛОГИЧЕСКИ АКТИВНУЮ, СПЕЦИФИЧНУЮ В ОТНОШЕНИИ СЕТЧАТКИ ГУАНИЛАТЦИКЛАЗУ ЧЕЛОВЕКА, СПОСОБНЫЙ ПРЕДОХРАНЯТЬ ИЛИ ВОССТАНАВЛИВАТЬ ОПОСРЕДОВАННУЮ КОЛБОЧКАМИ ФУНКЦИЮ ГЛАЗА МЛЕКОПИТАЮЩЕГО
CN103505743A (zh)	2012-06-21	2014-01-15	北京命码生科科技有限公司	含功能性microRNA/siRNA的细胞微粒子及其应用
EP4012035B1 (en) *	2014-09-16	2024-11-06	Genzyme Corporation	Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
PT4012035T (pt) *	2014-09-16	2025-02-11	Genzyme Corp	Vetores virais adenoassociados para tratar o glaucoma de miocilina (mioc)
US10821193B2 (en) *	2014-09-16	2020-11-03	Genzyme Corporation	Adeno-associated viral vectors for treating myocilin (MYOC) glaucoma
GB201809588D0 (en) *	2018-06-12	2018-07-25	Univ Bristol	Materials and methods for modulating intraocular and intracranial pressure
WO2021072129A2 (en)	2019-10-08	2021-04-15	Trustees Of Boston College	Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
US20230085724A1 (en)	2020-03-05	2023-03-23	Neotx Therapeutics Ltd.	Methods and compositions for treating cancer with immune cells
JP2023527578A (ja) *	2020-06-05	2023-06-29	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	眼疾患を処置するための方法及び医薬組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2410828C (en) *	2000-06-01	2012-01-24	University Of North Carolina At Chapel Hill	Duplexed parvovirus vectors
US20040209832A1 (en) *	2001-11-30	2004-10-21	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) *	2002-02-20	2005-03-03	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) *	2001-11-30	2004-10-07	Mcswiggen James	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
SG145713A1 (en) *	2003-08-13	2008-09-29	Univ Illinois	SILENCING OF TGFss TYPE II RECEPTOR EXPRESSION BY SIRNA
WO2006042252A2 (en) *	2004-10-08	2006-04-20	Potentia Pharmeceuticals, Inc.	Viral complement control proteins for eye disorders
TWI386225B (zh) *	2004-12-23	2013-02-21	Alcon Inc	用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
TWI401316B (zh) *	2004-12-23	2013-07-11	Alcon Inc	用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
TW200639252A (en) *	2005-02-01	2006-11-16	Alcon Inc	RNAi-mediated inhibition of ocular hypertension targets
BRPI0609206A2 (pt) *	2005-03-11	2010-03-02	Alcon Inc	inibiÇço mediada por rnai de proteÍna relacionada frizzled-1 para tratamento de glaucoma
GB0521351D0 (en) *	2005-10-20	2005-11-30	Genomica Sau	Modulation of TRPV expression levels
AR057252A1 (es) *	2005-12-27	2007-11-21	Alcon Mfg Ltd	Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
TW200731980A (en) *	2005-12-29	2007-09-01	Alcon Mfg Ltd	RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
TW200808360A (en) *	2006-04-13	2008-02-16	Alcon Mfg Ltd	RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
US8298818B2 (en) *	2006-04-28	2012-10-30	University Of Florida Research Foundation, Inc.	Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
US7732421B2 (en) *	2006-05-19	2010-06-08	Alcon Research, Ltd.	RNAI-mediated inhibition of tumor necrosis factor α-related conditions
CN102743767A (zh) *	2006-08-24	2012-10-24	爱尔康研究有限公司	RNAi介导的Gremlin抑制用于治疗眼内压相关的状况
JP2010518880A (ja) *	2007-02-26	2010-06-03	クアーク・ファーマスーティカルス、インコーポレイテッド	Ｒｔｐ８０１のインヒビター及びその疾患の治療における使用
US7973019B1 (en) *	2007-10-03	2011-07-05	Alcon Research, Ltd.	Transferrin/transferrin receptor-mediated siRNA delivery
AR069704A1 (es) *	2007-12-18	2010-02-10	Alcon Res Ltd	Sistema de administracion de rnai de interferencia y usos del mismo

2008
- 2008-10-01 CN CN200880110028A patent/CN101815536A/zh active Pending
- 2008-10-01 WO PCT/US2008/078380 patent/WO2009046059A1/en not_active Ceased
- 2008-10-01 AU AU2008308784A patent/AU2008308784B2/en not_active Ceased
- 2008-10-01 JP JP2010527251A patent/JP2010540564A/ja active Pending
- 2008-10-01 EP EP08835867A patent/EP2192926A1/en not_active Withdrawn
- 2008-10-01 US US12/243,100 patent/US20090087413A1/en not_active Abandoned
- 2008-10-01 MX MX2010001608A patent/MX2010001608A/es not_active Application Discontinuation
- 2008-10-01 RU RU2010117178/15A patent/RU2010117178A/ru not_active Application Discontinuation
- 2008-10-01 CA CA2694091A patent/CA2694091A1/en not_active Abandoned
- 2008-10-01 BR BRPI0817937 patent/BRPI0817937A2/pt not_active IP Right Cessation
- 2008-10-01 KR KR1020107003620A patent/KR20100061792A/ko not_active Withdrawn
2010
- 2010-01-20 ZA ZA2010/00423A patent/ZA201000423B/en unknown

Also Published As

Publication number	Publication date
JP2010540564A (ja)	2010-12-24
US20090087413A1 (en)	2009-04-02
AU2008308784B2 (en)	2013-07-18
RU2010117178A (ru)	2011-11-10
WO2009046059A1 (en)	2009-04-09
CA2694091A1 (en)	2009-04-09
EP2192926A1 (en)	2010-06-09
CN101815536A (zh)	2010-08-25
KR20100061792A (ko)	2010-06-09
MX2010001608A (es)	2010-03-15
ZA201000423B (en)	2011-03-30
AU2008308784A1 (en)	2009-04-09

Publication	Publication Date	Title
BRPI0817937A2 (pt)	2015-04-07	Entrega mediada por aav autocomplementar de moléculas de rna de interferência para tratar ou prevenir distúrbios oculares
BRPI0919920A2 (pt)	2016-02-16	compostos para tratamento de doenças e desordens oftálmicas
PT2444424T (pt)	2018-11-09	Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação
BRPI0919288A2 (pt)	2015-12-15	teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0817775A2 (pt)	2015-03-24	Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas
BRPI0812755A2 (pt)	2014-09-30	Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
BR112014026285A2 (pt)	2017-06-27	oligonucleotídeos moduladores de rna com características melhoradas para o tratamento de distúrbios neuromusculares
BRPI0918527A2 (pt)	2015-12-01	compostos para o tratamento de disturbios do cns
BRPI0807987A2 (pt)	2014-06-24	Terapia de combinação para tratamento de distúrbios imunes.
PT2499249T (pt)	2018-11-21	Moléculas antisentido e métodos para tratar patologias
BRPI0814624A2 (pt)	2015-01-27	Tratamento de doença neurodegenerativa progresiva com ibudilaste
BRPI0812768A2 (pt)	2014-12-02	Igf para o tratamento de síndrome de rett e transtornos sinápticos.
BRPI0905614A2 (pt)	2015-06-30	"processo para tratamento de efluentes líquidos e sólidos"
BRPI0816175A2 (pt)	2015-02-24	Composições adequadas para tratamento de doença, distúrbio ou condição da espinha.
DK2929031T3 (da)	2018-01-29	Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
BRPI0908026A2 (pt)	2015-07-21	Métodos para o tratamento de doenças do intestino
BRPI1010868A2 (pt)	2018-06-12	terapia gênica para distúrbios neurodegenerativos
BRPI0917440A2 (pt)	2015-12-01	composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BRPI0909817A2 (pt)	2017-06-13	uso de células-tronco mesenquimais para tratamento de doenças e distúrbios genéticos
BRPI0908334A2 (pt)	2018-01-30	kit, composição, produto ou medicamento para tratar comprometimento cognitivo
PT2501234T (pt)	2017-12-13	Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
EP2195027A4 (en)	2011-11-16	METHOD FOR THE TREATMENT OF NEUROLOGICAL AUTOIMMUNE DISEASES WITH CYCLOPHOSPHAMID
BRPI0816712A2 (pt)	2016-11-08	terapia de intervalo para o tratamento de tinnitus
PL2307000T3 (pl)	2014-09-30	Połączenie pilokarpiny i metimazolu do leczenia choroby Charcota-Mariegotootha i pokrewnych zaburzeń
BRPI0810091A2 (pt)	2014-10-21	Agentes fugicidas tópicos para tratar distúrbios ungueais

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.